The Joint Corp. (NASDAQ:JYNT) Receives $22.00 Average PT from Analysts

Shares of The Joint Corp. (NASDAQ:JYNT) have been given an average rating of “Moderate Buy” by the four ratings firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $22.00.

JYNT has been the topic of several research reports. Roth Mkm restated a “buy” rating and issued a $16.00 target price (up previously from $13.00) on shares of Joint in a report on Friday, May 3rd. StockNews.com raised Joint from a “hold” rating to a “buy” rating in a report on Monday. TheStreet downgraded Joint from a “c-” rating to a “d” rating in a research note on Thursday, March 7th. Finally, B. Riley increased their target price on shares of Joint from $12.00 to $20.00 and gave the stock a “buy” rating in a report on Monday.

Joint Price Performance

Shares of NASDAQ:JYNT opened at $15.93 on Monday. Joint has a 1 year low of $7.31 and a 1 year high of $16.39. The company has a market cap of $238.54 million, a P/E ratio of -21.24 and a beta of 1.58. The stock’s fifty day moving average price is $12.42 and its 200-day moving average price is $10.31.

Joint (NASDAQ:JYNT) last posted its earnings results on Thursday, March 7th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.04. The business had revenue of $30.61 million for the quarter, compared to analysts’ expectations of $29.63 million. Joint had a negative net margin of 9.24% and a positive return on equity of 3.94%. On average, sell-side analysts anticipate that Joint will post 0.13 earnings per share for the current year.

Hedge Funds Weigh In On Joint

Hedge funds and other institutional investors have recently modified their holdings of the stock. Strs Ohio lifted its stake in Joint by 69.1% in the 3rd quarter. Strs Ohio now owns 25,200 shares of the company’s stock worth $226,000 after purchasing an additional 10,300 shares in the last quarter. Skylands Capital LLC increased its holdings in shares of Joint by 24.5% in the third quarter. Skylands Capital LLC now owns 501,790 shares of the company’s stock worth $4,511,000 after purchasing an additional 98,900 shares during the last quarter. Verus Capital Partners LLC boosted its stake in Joint by 24.0% during the third quarter. Verus Capital Partners LLC now owns 108,370 shares of the company’s stock valued at $974,000 after buying an additional 20,950 shares during the last quarter. Barclays PLC grew its holdings in Joint by 29.4% during the 3rd quarter. Barclays PLC now owns 13,725 shares of the company’s stock valued at $123,000 after buying an additional 3,119 shares in the last quarter. Finally, Quantbot Technologies LP increased its stake in Joint by 345.0% in the 3rd quarter. Quantbot Technologies LP now owns 4,170 shares of the company’s stock worth $37,000 after acquiring an additional 3,233 shares during the last quarter. Institutional investors own 76.88% of the company’s stock.

Joint Company Profile

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.